Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.
Arrowhead gets another big pharma partner in GSK

GlaxoSmithKline plcmoves into non-alcoholic steatohepatitis (NASH) R&D with a mid-stage RNA-interference candidate, while Arrowhead Pharmaceuticals, Inc. turns a candidate that it did not plan to commercialize itself into a revenue source as it frees itself up to focus R&D spending on candidates that it can take to market in smaller patient populations. Those were the rationales offered for a licensing deal announced on 22 November between GSK and Arrowhead during a time of high development risk in the NASH space.

The UK-headquartered pharma will pay Arrowhead $120m up front for development and commercial rights to ARO-HSD, a Phase I/II therapy...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.